Puration Inc PURA and Kali-Extracts KALY said Monday that a planned acquisition by Pura of Kaly's CBD confections operations is underway.
Kaly is focusing its business on cannabis extract biopharmaceuticals, and its leading research has been on the treatment of respiratory conditions, the companies said.
Kaly has filed a new patent application on its CBD formulation for the symptoms of COPD and similar respiratory conditions, the companies said. The company has also filed for a trademark on the name RespRx as a brand of CBD for COPD symptoms and other conditions that cause respiratory inflammation.
The company said it is evaluating its proprietary CBD extract formulation as a treatment for symptoms of coronavirus.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
